คำอธิบาย
Diltiazem increases dabigatran plasma levels through P-glycoprotein inhibition, potentially raising bleeding risk without a change in INR (dabigatran has no INR to monitor).
กลไก
Dabigatran etexilate (prodrug) is a substrate of intestinal P-glycoprotein; diltiazem inhibits P-gp, increasing dabigatran absorption and systemic exposure.
ความสำคัญทางคลินิก
Dabigatran AUC increases approximately 20–40%; clinically significant in patients with renal impairment who already have reduced dabigatran clearance.
การจัดการ
Monitor for bleeding symptoms; consider dabigatran dose reduction in patients with moderate renal impairment who require diltiazem.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.